Intuitive Surgical, Inc. $ISRG Stock Bought by Factory Mutual Insurance Co.

Factory Mutual Insurance Co. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 41.7% during the third quarter, Holdings Channel reports. The firm owned 188,198 shares of the medical equipment provider’s stock after purchasing an additional 55,373 shares during the period. Factory Mutual Insurance Co.’s holdings in Intuitive Surgical were worth $76,527,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Gerber Kawasaki Wealth & Investment Management lifted its position in Intuitive Surgical by 6.4% in the third quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,807 shares of the medical equipment provider’s stock valued at $1,141,000 after acquiring an additional 170 shares during the last quarter. GraniteShares Advisors LLC boosted its stake in Intuitive Surgical by 4.8% in the third quarter. GraniteShares Advisors LLC now owns 2,601 shares of the medical equipment provider’s stock valued at $1,058,000 after acquiring an additional 118 shares in the last quarter. BOCHK Asset Management Ltd grew its holdings in shares of Intuitive Surgical by 64.6% during the third quarter. BOCHK Asset Management Ltd now owns 10,700 shares of the medical equipment provider’s stock worth $4,351,000 after purchasing an additional 4,200 shares during the last quarter. Blue Bell Private Wealth Management LLC grew its holdings in shares of Intuitive Surgical by 164.6% during the third quarter. Blue Bell Private Wealth Management LLC now owns 434 shares of the medical equipment provider’s stock worth $176,000 after purchasing an additional 270 shares during the last quarter. Finally, Greenfield Seitz Capital Management LLC grew its holdings in shares of Intuitive Surgical by 56.1% during the third quarter. Greenfield Seitz Capital Management LLC now owns 22,096 shares of the medical equipment provider’s stock worth $8,985,000 after purchasing an additional 7,945 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $440.75 on Wednesday. The company has a market cap of $152.78 billion, a P/E ratio of 53.30, a PEG ratio of 3.01 and a beta of 1.45. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88. The firm has a fifty day moving average of $404.05 and a two-hundred day moving average of $432.90.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping the consensus estimate of $2.65 by $0.35. The company had revenue of $3.05 billion during the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The business’s revenue was up 21.7% on a year-over-year basis. During the same quarter last year, the business earned $2.40 EPS. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on ISRG. Robert W. Baird lifted their target price on Intuitive Surgical from $513.00 to $550.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 21st. TD Cowen restated a “buy” rating and set a $485.00 price target on shares of Intuitive Surgical in a research note on Monday, October 19th. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a research note on Friday, August 14th. Stifel Nicolaus cut their price target on Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating on the stock in a research report on Friday, July 17th. Finally, BNP Paribas Exane upgraded Intuitive Surgical to an “outperform” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $493.54.

Insider Activity

In related news, Director Gary S. Guthart sold 20,095 shares of the firm’s stock in a transaction dated Friday, October 23rd. The shares were sold at an average price of $451.61, for a total value of $9,075,102.95. Following the completion of the sale, the director owned 1,204,530 shares in the company, valued at $543,977,793.30. This trade represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the sale, the director directly owned 251 shares in the company, valued at $95,129. This represents a 61.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 38,778 shares of company stock valued at $16,814,967 over the last ninety days. 0.60% of the stock is currently owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.